-
Je něco špatně v tomto záznamu ?
Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET
S. van der Gaag, AN. Vis, IH. Bartelink, JCC. Koppes, M. Hodolic, H. Hendrikse, DE. Oprea-Lager
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antigeny povrchové * metabolismus MeSH
- benzamidy * MeSH
- fenylthiohydantoin * terapeutické užití analogy a deriváty MeSH
- glutamátkarboxypeptidasa II * metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci * farmakoterapie diagnostické zobrazování metabolismus MeSH
- nitrily * terapeutické užití MeSH
- PET/CT * MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- upregulace * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
Androgen receptor-targeting agents, particularly enzalutamide, show promise in enhancing prostate cancer diagnostic and therapeutic strategies by modulating prostate-specific membrane antigen (PSMA). Methods: A retrospective clinical cohort study investigated 9 men with metastatic castration-resistant prostate cancer on enzalutamide. PSMA PET/CT scans were obtained before and after enzalutamide initiation to assess PSMA expression changes. Lesions and organs at risk were evaluated visually and semiquantitatively. The flare phenomenon was characterized by a significant increase (≥20%) in the SUVmax of existing lesions or the appearance of new PSMA-positive lesions. Results: Exposure to enzalutamide led to a significant PSMA expression increase in 56% of assessed lesions (n = 42), with new lesions detected in 1 patient (11%). PSMA expression in organs at risk remained largely unaffected, indicating a tumor-specific response. Conclusion: Enzalutamide induces PSMA upregulation in metastatic castration-resistant prostate cancer, potentially enhancing diagnostic and therapeutic strategies. Further exploration of the flare phenomenon's clinical implications is warranted.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009581
- 003
- CZ-PrNML
- 005
- 20250429135051.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2967/jnumed.124.268340 $2 doi
- 035 __
- $a (PubMed)39915123
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a van der Gaag, Suzanne $u Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands $u Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 245 10
- $a Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET / $c S. van der Gaag, AN. Vis, IH. Bartelink, JCC. Koppes, M. Hodolic, H. Hendrikse, DE. Oprea-Lager
- 520 9_
- $a Androgen receptor-targeting agents, particularly enzalutamide, show promise in enhancing prostate cancer diagnostic and therapeutic strategies by modulating prostate-specific membrane antigen (PSMA). Methods: A retrospective clinical cohort study investigated 9 men with metastatic castration-resistant prostate cancer on enzalutamide. PSMA PET/CT scans were obtained before and after enzalutamide initiation to assess PSMA expression changes. Lesions and organs at risk were evaluated visually and semiquantitatively. The flare phenomenon was characterized by a significant increase (≥20%) in the SUVmax of existing lesions or the appearance of new PSMA-positive lesions. Results: Exposure to enzalutamide led to a significant PSMA expression increase in 56% of assessed lesions (n = 42), with new lesions detected in 1 patient (11%). PSMA expression in organs at risk remained largely unaffected, indicating a tumor-specific response. Conclusion: Enzalutamide induces PSMA upregulation in metastatic castration-resistant prostate cancer, potentially enhancing diagnostic and therapeutic strategies. Further exploration of the flare phenomenon's clinical implications is warranted.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fenylthiohydantoin $x terapeutické užití $x analogy a deriváty $7 D010669
- 650 12
- $a nitrily $x terapeutické užití $7 D009570
- 650 12
- $a benzamidy $7 D001549
- 650 12
- $a nádory prostaty rezistentní na kastraci $x farmakoterapie $x diagnostické zobrazování $x metabolismus $7 D064129
- 650 12
- $a glutamátkarboxypeptidasa II $x metabolismus $7 D043425
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a upregulace $7 D015854
- 650 12
- $a antigeny povrchové $x metabolismus $7 D000954
- 650 12
- $a PET/CT $7 D000072078
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři nad 80 let $7 D000369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vis, André N $u Department of Urology, Prostate Cancer Network Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; a.vis@amsterdamumc.nl
- 700 1_
- $a Bartelink, Imke H $u Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands $u Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and
- 700 1_
- $a Koppes, Josephina C C $u Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands $u Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Hodolic, Marina $u Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Hendrikse, Harry $u Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands $u Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Oprea-Lager, Daniela E $u Department of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands $u Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands
- 773 0_
- $w MED00010072 $t The Journal of nuclear medicine $x 1535-5667 $g Roč. 66, č. 3 (2025), s. 373-376
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39915123 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135046 $b ABA008
- 999 __
- $a ok $b bmc $g 2311142 $s 1246662
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 66 $c 3 $d 373-376 $e 20250303 $i 1535-5667 $m The Journal of nuclear medicine $n J Nucl Med $x MED00010072
- LZP __
- $a Pubmed-20250415
